AI Article Synopsis
- Liver cancer is a significant global health issue, being the sixth most common cancer and a leading cause of cancer deaths, particularly affecting males in Saudi Arabia.
- The study reviewed liver cancer cases from 2014 to 2020, documenting 3066 diagnoses among Saudi Nationals, with Hepatocellular carcinoma being the most prevalent type.
- The incidence rates for liver cancer showed a higher occurrence in males compared to females, highlighting a need to focus on risk factors for better prevention and care strategies.
Article Abstract
Liver cancer is a major worldwide health concern characterized by increasing rates of occurrence. It ranks as the sixth most prevalent form of cancer and is the third highest contributor to cancer-related fatalities globally. This study aimed to describe the epidemiology of liver cancer in Saudi Arabia and to analyze the factors associated with it. This retrospective medical record review included all the patients diagnosed with a liver cancer from January 2014 to December 2020. The incidence data were obtained and collected from the Saudi Cancer registry. The net survival percentage was obtained in global cancer observatory website of the International Agency for Research on Cancer. There were 3066 occurrences of liver cancer among Saudi Nationals during the years 2014 and 2020. The majority of patients consisted of males, accounting for 2105 individuals, which represents 68.7 % of the total. The predominant morphologies are Hepatocellular carcinoma (2520, 82.2 %), choliangocarcinoma (267, 8.7 %), Adenocarcinoma (5.1 %), and malignant neoplasm (3.4 %). The age-standardized incidence rate for males between 2014 and 2020 varied from 4.0 per 100,000 to 4.8 per 100,000, whilst for females it ranged from 1.5 per 100,000 to 2.4 per 100,000. The age-standardized incidence rate among Saudi nationals is 4.7 cases per 100,000, while the age-standardized mortality rate is 4.6 deaths per 100,000. Liver cancer is a significant global health problem, marked by its high occurrence and typically poor survival rates. By emphasizing risk factors, it enhances the implementation practices that may help to provide appropriate care to maximize favourable outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.canep.2024.102731 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing the feasibility and external validity of natural language processing-extracted data for advanced lung cancer patients.
Lung Cancer
January 2025
Dept. of Medical Oncology, Princess Margaret Cancer Center, Toronto, ON, Canada.
Background: Manual extraction of real-world clinical data for research can be time-consuming and prone to error. We assessed the feasibility of using natural language processing (NLP), an AI technique, to automate data extraction for patients with advanced lung cancer (aLC). We assessed the external validity of our NLP-extracted data by comparing our findings to those reported in the literature.
View Article and Find Full Text PDFPrediction of cccDNA dynamics in hepatitis B patients by a combination of serum surrogate markers.
PLoS Comput Biol
January 2025
Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Quantification of intrahepatic covalently closed circular DNA (cccDNA) is a key for evaluating an elimination of hepatitis B virus (HBV) in infected patients. However, quantifying cccDNA requires invasive methods such as a liver biopsy, which makes it impractical to access the dynamics of cccDNA in patients. Although HBV RNA and HBV core-related antigens (HBcrAg) have been proposed as surrogate markers for evaluating cccDNA activity, they do not necessarily estimate the amount of cccDNA.
View Article and Find Full Text PDFEna-bile-ing liver cancer growth.
Science
January 2025
Gastroenterology Division, Massachusetts General Hospital, Boston, MA, USA.
Bile acids differentially affect immune cell responses to liver cancer.
View Article and Find Full Text PDFBile acid synthesis impedes tumor-specific T cell responses during liver cancer.
Science
January 2025
NOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA, USA.
The metabolic landscape of cancer greatly influences antitumor immunity, yet it remains unclear how organ-specific metabolites in the tumor microenvironment influence immunosurveillance. We found that accumulation of primary conjugated and secondary bile acids (BAs) are metabolic features of human hepatocellular carcinoma and experimental liver cancer models. Inhibiting conjugated BA synthesis in hepatocytes through deletion of the BA-conjugating enzyme bile acid-CoA:amino acid -acyltransferase (BAAT) enhanced tumor-specific T cell responses, reduced tumor growth, and sensitized tumors to anti-programmed cell death protein 1 (anti-PD-1) immunotherapy.
View Article and Find Full Text PDFResearch on the mechanism of eugenol in the treatment of liver cancer based on network pharmacology, molecular docking technology, and in vitro experiments.
Anticancer Drugs
January 2025
School of Clinical Medicine, Guizhou Medical University, Guiyang City, Guizhou, China.
Eugenol, a phenolic natural product with diverse pharmacological activities, remains unexplored in liver cancer. Using network pharmacology, we investigated eugenol's therapeutic mechanisms in liver cancer. We obtained eugenol's molecular structure from PubChem and screened its targets using similarity ensemble approach in Swiss Target Predictiondatabases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!